News – Page 1170 – Endpoints News

Protocols: Cell Medica strikes a TCR research deal with University College London; UK offers early access to AbbVie's ...

9 years ago

BioRegnum: The mob is back. And what's to stop them from going after the entire biopharma industry?

9 years ago

Still in spotlight of a federal probe, Insys touts PhIII pain study as it preps an NDA

9 years ago

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

9 years ago

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

9 years ago

Protocols: Mylan’s EpiPen strategy stirs fresh outrage over price gouging; a flailing Woodford halts big bonuses

9 years ago

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib

9 years ago

Tokai retreats from the clinic after lead drug implodes in PhIII

9 years ago

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

9 years ago

Little Stemline grabs a big ‘breakthrough’ title for its pivotal-stage cancer drug

9 years ago

Google Ventures’ Krishna Yeshwant is hunting for the next big new idea in biotech

9 years ago

Protocols: Editas recruits a Bristol-Myers vet as CSO; Eli Lilly gets a dubious honor for Alzheimer's drug; Voyager ...

9 years ago

Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown

9 years ago

BioRegnum snapshot: Who are the real insiders when it comes to healthcare policy?

9 years ago

Low-profile Thar Pharma takes a $50M flier on a weak IPO market

9 years ago

Axel Bouchon starts signing players for a new league of game-changing biotechs

9 years ago

Pfizer bags Medivation buyout with blowout $14B cash offer

9 years ago

Protocols: Calico recruits a machine learning star for computational biology; OncoMed raises $55M

9 years ago

Golden Triangle gets £75M in fresh venture funds for Cambridge U spinouts

9 years ago

Chinese development group blueprints $1B-plus biotech campus in South San Francisco

9 years ago

Thumbs Up. Thumbs Down: On rookie mistakes, a class action suit and getting past failure

9 years ago

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

9 years ago

Following another PhII failure, cash-strapped Cerulean chops half its staff

9 years ago

Protocols: Mallinckrodt lands a new corporate campus in NJ; Nutrinia bags a $30M round for oral insulin

9 years ago

First page Previous page 1167 1168 116911701171 1172 1173 Next page Last page